Gadoquatrane showed pediatric safety and pharmacokinetic profiles similar to adults in a study, supporting use as a low-dose ...
Gadolinium-based contrast agents (GBCAs) used in MRI and angiography contain a chelated form of the toxic heavy metal that was assumed to clear the body shortly after intravenous administration. [1] ...
Compared to group I GBCAs, group II GBCAs appear safe for use in patients with severe kidney disease. In a recent analysis, the risk of NSF in patients with stage 4 or 5 CKD was less than 0.07% with ...
Contrast chemicals injected into people for medical imaging scans are likely contributing to water pollution, a new study ...
BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...
CAMBRIDGE, Mass. -- A new, specially coated iron oxide nanoparticle developed by a team at MIT and elsewhere could provide an alternative to conventional gadolinium-based contrast agents used for ...
GE HealthCare has announced positive results from a Phase I study of its manganese-based macrocyclic magnetic resonance imaging (MRI) contrast agent. Data from the first-in-human trial – presented at ...
A comprehensive study by the CritMET research group, led by Prof. Michael Bau, a geochemist at Constructor University in Bremen, provides evidence of widespread contamination of the North Sea and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback